Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10348MR)

This product GTTS-WQ10348MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 10673
UniProt ID Q16552; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10348MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ301MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ916MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ1393MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ5312MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ3943MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ3618MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ2560MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ4384MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW